<DOC>
	<DOCNO>NCT00796692</DOCNO>
	<brief_summary>Low-molecular-weight heparin ( LWMH ) appear least effective safe standard , unfractionated heparin ( UFH ) treatment patient deep vein thrombosis ( DVT ) may also patient pulmonary thromboembolism ( PTE ) . Only limited data available evaluation body weight adjust LWMH standard UFH initial treatment PTE Chinese population . The aim study determine whether body weight-adjusted , subcutaneous Nadroparin effective safe UFH treatment patient objectively document PTE .</brief_summary>
	<brief_title>Nadroparin Initial Treatment Pulmonary Thromboembolism</brief_title>
	<detailed_description>Low-molecular-weight heparin ( LWMH ) appear least effective safe standard , unfractionated heparin ( UFH ) treatment patient deep vein thrombosis ( DVT ) may also patient pulmonary thromboembolism ( PTE ) . Only limited data available evaluation body weight adjust LWMH standard UFH initial treatment PTE Chinese population . The aim study determine whether body weight-adjusted , subcutaneous Nadroparin effective safe UFH treatment patient objectively document PTE . An open-label , adjudicator-blinded , randomize controlled trial patient symptomatic non-massive PTE 37 major hospital China conduct . Intravenous UFH administer receive initial bolus dose 80 IU/kg , follow continuous infusion initial rate 18 IU/kg /hour . The dose subsequently adjust activate partial thromboplastin time ( APTT ) monitoring . LMWH ( nadroparin ) administer subcutaneously dose 86 anti-factor Xa IU/kg every 12 hour . Both treatment overlap least 3 month warfarin therapy . Main outcome measure combine end point clinical effect , image improvement , Recurrent venous thromboembolism ( VTE ) , major bleeding , death within 14 day 3 month randomization .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<criteria>18 75 year age Symptomatic non massive PTE confirm either high probability ventilationperfusion lung scanning ( V/Q scan ) presence intraluminal filling defect spiral compute tomographic pulmonary angiography ( CTPA ) Haemodynamic stabile , anatomic obstruction 2 lobe CTPA , defect 7 segment V/Q scan , normal right ventricular function Symptoms within 15 day Written inform consent obtain randomization . Unfractioned heparin anticoagulation 36 hour prior enrollment , Massive PTE submassive PTE require thrombolytic therapy pulmonary embolectomy ; Active bleeding disorder contraindicate anticoagulant therapy Chronic thromboembolism pulmonary hypertension ( CTEPH ) without evidence recent episode ; Severe hepatic renal failure Allergy heparin , component Tinzaparin acenocoumarol , Pregnant status ; life expectancy le 3 month ; Previous thrombocytopenia induce heparin Thrombocytopenia &lt; 100000/mm3 ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Heparin</keyword>
	<keyword>Low molecular weight heparin</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Cost effective</keyword>
</DOC>